Highlights

  • Pharmx Technologies has set Wednesday 25 November 2026 as the date for its 2026 Annual General Meeting.
  • The deadline for new director nominations to be received is Wednesday 7 October 2026.
  • Pharmx operates a pharmacy ordering platform connecting pharmacies, suppliers and technology vendors across Australia and New Zealand.
  • The company describes its platform as facilitating approximately $20 billion in transactions annually.

Pharmx Technologies Limited (ASX:PHX) has advised the market of the indicative key dates relating to its 2026 Annual General Meeting. The company has set Wednesday 25 November 2026 as the date on which the meeting will be held, giving shareholders and prospective board candidates a clear timetable to work toward in the weeks ahead.

The Director Nomination Window

Alongside the meeting date, Pharmx has confirmed that the last date for new director nominations to be received is Wednesday 7 October 2026. This nomination window gives eligible parties a defined period in which to put forward candidates for consideration ahead of the AGM, a standard governance step for ASX-listed companies preparing for their annual Shareholder meeting.

Pharmx's Position in the Pharmacy Technology Sector

Pharmx describes itself as a leading pharmacy ordering platform across Australia and New Zealand, providing infrastructure that connects a large network of pharmacies, suppliers and technology vendors for ordering and inventory management. The company has said its platform facilitates approximately $20 billion in transactions annually through its ordering, eInvoicing and analytics solutions, positioning it within the broader healthtech and pharmacy technology sector.

Key Insights

The confirmation of key AGM dates is a routine but necessary governance step for any ASX-listed company, giving shareholders visibility on when the meeting will take place and when nominations for new directors close. For Pharmx, this notice comes as the company continues to describe itself as a significant piece of transactional infrastructure within the Australian and New Zealand pharmacy sector. Shareholders and prospective director candidates now have a clear timetable to plan around ahead of the 25 November 2026 meeting.